Category Archives: BAP1

DNA

ToxicoGenomica at the DRI Toxic Torts and Environmental Law Seminar 2025: Tackling the Impediments to Obtaining and Using Genetic Testing in Toxic Tort Cases

| May 15, 2025

Dr. Len Van Zyl of ToxicoGenomica recently joined a distinguished panel at the 2025 Toxic Torts and Environmental Law Seminar, held from March 26-28 in Atlanta. The panel, titled Offense is the Best Defense: Tackling the Impediments to Obtaining and Using Genetic Testing in Toxic Tort Cases, explored the latest scientific studies on genetic causation […]

Learn More
DNA

Perrin Conferences Presents: 2023 Brings Multiple Waves of Additional Studies Regarding Mesotheliomas and Other Cancers Caused Solely by Genomic Factors

| June 1, 2023

Join us for this complimentary CLE webinar on Tuesday, July 18, 2023 from 2:00-3:30 pm ET. This webinar will focus on the latest publications, scientific studies, and statistics regarding genomics role in cancers. It will also cover predictive software and other tools for understanding the impact of germline mutations on disease development and progression. There […]

Learn More

Key Developments in the Use of Genomics in Mesothelioma Cases: Causal Role of BAP1 Null (Loss of Function) Mutations in Mesothelioma and Key Legal Findings

| December 19, 2022

ToxicoGenomica recently presented a webinar organized by Perrin Conferences and the slides are now available for download. The title of the session was Key Developments: Genomics in Mesothelioma Cases. The webinar focused on the latest cases, the most recent science and publications, and the evolving applications and cost of deployment of the science of genomics […]

Learn More

Upcoming Perrin Conference on Cutting-Edge Issues in Asbestos Litigation: Beverly Hills, CA

| March 3, 2022

The use of genomic analysis to evaluate mesothelioma causation is a topic that will be covered at the upcoming Perrin Conference on Cutting-Edge Issues in Asbestos Litigation. As part of a panel, ToxicoGenomica’s Kirk Hartley will discuss several topics at the intersections between genomic science and law. One portion of his talk will focus on […]

Learn More
conference

The Time for Genomic Analyses in Asbestos Cases is Now

| July 14, 2019

Expert testimony involving genetic findings is more and more common in asbestos litigation. Recent studies published in the peer-reviewed scientific literature have evaluated a variety of genetic factors (e.g., inherited genetic mutations, micro-RNA, gene expression profiles, and epigenetic factors) in people with and without asbestos exposure. Investigators have found evidence to support the fact that […]

Learn More
DNA

Why Do BAP1 Mutations Cause Mesothelioma?

| May 6, 2019

Mechanistic understanding of cancers continues to accelerate, with important implications for tort litigation. A recent new study by He et al. (2019) provides new insights into how and why germline BAP1 mutations are involved in the development of some cancers, such as mesothelioma, but not others. The new insights are about tissue specific actions of […]

Learn More
Scientist looking at DNA

The Meso Gene [Download ACI Presentations]

| June 12, 2018

The ongoing revolution in genomic science is having an impact on many facets of modern life, including toxic tort litigation. This point was apparent at the recently held American Conference Institute’s 23rd National Forum on Asbestos Claims & Litigation (May 21-23, 2018) in Chicago, where we presented in a session titled “The Meso Gene.” In […]

Learn More
Litigators Guide to a Genomic Defense

The Litigator’s Guide to Using Genomics in a Toxic Tort Case

| June 11, 2018

Genomics is a proven and reliable quantitative tool that has dramatically improved cancer treatment, established the practice of personalized medicine, and brought binary clarity to paternity and criminal cases. Genomics is now transforming how civil toxic tort cases are adjudicated. We have hit a tipping point where, instead of merely relying on population-based epidemiological studies, […]

Learn More
uch bard1

New and Notable Findings on the Role of BAP1 in Some Cancers – Why They Matter to Litigators

| January 9, 2018

In June 2017, International leaders in mesothelioma research reported the results of their latest study describing the roles of  BAP1 mutations in cancer. Their findings were reported in perhaps the top international medical journal (Nature), as well as a much less formal popular press article. The less formal article was titled “Dr. Michele Carbone and […]

Learn More